CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer

Richard R. Love, Zeruesenay Desta, David Flockhart, Todd Skaar, Evan T. Ogburn, Anuradha Ramamoorthy, Gemma B. Uy, Adriano V. Laudico, Nguyen van Dinh, Le Hong Quang, Ta van To, Gregory S. Young, Erinn Hade, David Jarjoura

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case-control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control. Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may promote recurrence.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalSpringerPlus
Volume2
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Genotype
Breast Neoplasms
Recurrence
4-hydroxy-N-desmethyltamoxifen
Proportional Hazards Models
Case-Control Studies
Clinical Trials

ASJC Scopus subject areas

  • General

Cite this

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. / Love, Richard R.; Desta, Zeruesenay; Flockhart, David; Skaar, Todd; Ogburn, Evan T.; Ramamoorthy, Anuradha; Uy, Gemma B.; Laudico, Adriano V.; van Dinh, Nguyen; Quang, Le Hong; van To, Ta; Young, Gregory S.; Hade, Erinn; Jarjoura, David.

In: SpringerPlus, Vol. 2, No. 1, 2013, p. 1-5.

Research output: Contribution to journalArticle

Love, RR, Desta, Z, Flockhart, D, Skaar, T, Ogburn, ET, Ramamoorthy, A, Uy, GB, Laudico, AV, van Dinh, N, Quang, LH, van To, T, Young, GS, Hade, E & Jarjoura, D 2013, 'CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer', SpringerPlus, vol. 2, no. 1, pp. 1-5. https://doi.org/10.1186/2193-1801-2-52
Love, Richard R. ; Desta, Zeruesenay ; Flockhart, David ; Skaar, Todd ; Ogburn, Evan T. ; Ramamoorthy, Anuradha ; Uy, Gemma B. ; Laudico, Adriano V. ; van Dinh, Nguyen ; Quang, Le Hong ; van To, Ta ; Young, Gregory S. ; Hade, Erinn ; Jarjoura, David. / CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. In: SpringerPlus. 2013 ; Vol. 2, No. 1. pp. 1-5.
@article{2bbc61bc4964466eada153afac3c1ebb,
title = "CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer",
abstract = "Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case-control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control. Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may promote recurrence.",
author = "Love, {Richard R.} and Zeruesenay Desta and David Flockhart and Todd Skaar and Ogburn, {Evan T.} and Anuradha Ramamoorthy and Uy, {Gemma B.} and Laudico, {Adriano V.} and {van Dinh}, Nguyen and Quang, {Le Hong} and {van To}, Ta and Young, {Gregory S.} and Erinn Hade and David Jarjoura",
year = "2013",
doi = "10.1186/2193-1801-2-52",
language = "English (US)",
volume = "2",
pages = "1--5",
journal = "SpringerPlus",
issn = "2193-1801",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer

AU - Love, Richard R.

AU - Desta, Zeruesenay

AU - Flockhart, David

AU - Skaar, Todd

AU - Ogburn, Evan T.

AU - Ramamoorthy, Anuradha

AU - Uy, Gemma B.

AU - Laudico, Adriano V.

AU - van Dinh, Nguyen

AU - Quang, Le Hong

AU - van To, Ta

AU - Young, Gregory S.

AU - Hade, Erinn

AU - Jarjoura, David

PY - 2013

Y1 - 2013

N2 - Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case-control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control. Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may promote recurrence.

AB - Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case-control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control. Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may promote recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84876563989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876563989&partnerID=8YFLogxK

U2 - 10.1186/2193-1801-2-52

DO - 10.1186/2193-1801-2-52

M3 - Article

VL - 2

SP - 1

EP - 5

JO - SpringerPlus

JF - SpringerPlus

SN - 2193-1801

IS - 1

ER -